A randomized trial of 24-week versus 48-week courses of pegintereron plus ribavirin for genotype 1 hepatitis C and IL28B CC polymorphism.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Sep 2013 Planned End Date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 02 Oct 2011 New trial record